No Data
No Data
Express News | NanoViricides: Anil Diwan Visiting Professionals for Developing Phase II Clinical Trial Plan & Clinical Protocol for Phase II Clinical Trial of NV-387
Express News | NanoViricides: Plans on Exploring Effectiveness of NV-387 for Treatment of Severe Acute Respiratory Infections Caused by Viruses
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
The only manufacturer of smallpox vaccine has submitted clinical data and plans to expand the scope of vaccination.
Bavarian Nordic announced that it has submitted clinical data to the European Medicines Agency to seek an expansion of the indication for its Imvanex vaccine to adolescents aged 12-17. Yesterday, Sweden, the neighboring country of Denmark, reported the first confirmed case of monkeypox, which is also the first case confirmed outside the African continent since this epidemic outbreak.
NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could Be As Revolutionary as Antibiotics
"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides
No Data